Pfizer and 3SBio have finalized a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm's cancer drug, marking the largest deal ever for a single drug in China’s biotech industry.
26 Jul 2025-01:11
